The value of FDG PET/CT for follow-up of patients with melanoma:a retrospective analysis by Vensby, Philip H et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The value of FDG PET/CT for follow-up of patients with melanoma
Vensby, Philip H; Schmidt, Grethe; Kjær, Andreas; Fischer, Barbara M
Published in:
American Journal of Nuclear Medicine and Molecular Imaging
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Vensby, P. H., Schmidt, G., Kjær, A., & Fischer, B. M. (2017). The value of FDG PET/CT for follow-up of patients
with melanoma: a retrospective analysis. American Journal of Nuclear Medicine and Molecular Imaging, 7(6),
255-262.
Download date: 03. Feb. 2020
Am J Nucl Med Mol Imaging 2017;7(6):255-262
www.ajnmmi.us /ISSN:2160-8407/ajnmmi0067372
Original Article
The value of FDG PET/CT for follow-up of  
patients with melanoma: a retrospective analysis
Philip H Vensby1,2, Grethe Schmidt3, Andreas Kjær4, Barbara M Fischer5
1Department of Surgery, Gentofte and Herlev Hospital, Denmark; 2Department of Clinical Physiology, Nuclear 
Medicine and PET, Rigshospitalet, Denmark; 3Department of Plastic Surgery, Breast Surgery and Burns Treat-
ment, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 4Department of Clinical Physiol-
ogy, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, 
Denmark; 5Department of Clinical Physiology, Nuclear Medicine and PET Rigshospitalet, University of Copenha-
gen, Denmark
Received September 7, 2017; Accepted December 2, 2017; Epub December 20, 2017; Published December 30, 
2017
Abstract: The incidence of melanoma (MM) is among the fastest rising cancers in the western countries. Positron 
Emission Tomography with Computed Tomography (PET/CT) is a valuable non-invasive tool for the diagnosis and 
staging of patients with MM. However, research on the value of PET/CT in follow-up of melanoma patients is lim-
ited. This study assesses the diagnostic value of PET/CT for follow-up after melanoma surgery. This retrospective 
study includes patients with MM who performed at least one PET/CT scan after initial surgery and staging. PET/
CT findings were compared to histology, MRI or fine needle aspiration (FNA) to estimate the diagnostic accuracy. 
The diagnostic performance of PET/CT performed in patients with and without a clinical suspicion of relapse was 
compared. 238 patients (526 scans) were included. Of the 526 scans 130 (25%) scans were PET-positive, 365 
(69%) PET-negative, and 28 (5%) had equivocal findings. Sensitivity was 89% [0.82-0.94], specificity 92% [0.89-
0.95], positive and negative predictive values of 78% [0.70-0.84] and 97% [0.94-0.98] respectively. When stratified 
for reason of referral there was no statistical significant difference in the diagnostic accuracy of PET/CT between 
patients referred with or without a clinical suspicion of relapse. This study demonstrates that PET/CT despite a mod-
erate sensitivity has a high negative predictive value in the follow-up of melanoma patients. Thus, a negative PET/
CT-scan essentially rules out relapse. However, the frequency of false positive findings is relatively high, especially 
among patients undergoing a “routine” PET/CT with no clinical suspicion of relapse, potentially causing anxiety and 
leading to further diagnostic procedures.
Keywords: Melanoma, follow-up, surveillance, PET, PET/CT, cancer diagnostics, skin cancer, FDG, diagnostic 
accuracy
Introduction
Melanoma is among the most common can-
cers in the western world, and despite numer-
ous preventive campaigns there is a steady 
increase in incidence, in particular in Australia 
and northern Europe [1, 2]. As many as half of 
all patients treated for MM will eventually re- 
lapse [3]. Of these, approximately 20% will be 
local, 50% in regional lymph nodes, and 30% 
will relapse with distant metastases [4, 5], em- 
phasizing the importance of an efficient follow-
up program, enabling early detection of relapse 
while it is still amendable to treatment.
A conventional follow-up program includes me- 
dical history, palpation of lymph nodes and a 
general clinical examination as well as an as- 
sessment of the patient’s nevi. The frequency 
of follow-up visits and whether or not to in- 
clude imaging differs according to national 
guidelines. For the follow-up of patients with 
MM, recent reviews suggest a role for PET/ 
CT [6]. In Denmark PET and PET/CT has been 
widely used for follow-up of patients with higher 
stages of melanoma, with or without a clinical 
suspicion of relapse. Since 2015 PET/CT has 
been included in the Danish national follow up 
program as a routine examination at 6, 12 and 
24 months after treatment for MM (> stage IIB). 
In the US, the most recent guidelines from 
the National Comprehensive Cancer Network 
(NCCN Guidelines Version 1, 2017) suggests to 
consider Chest CT, brain MRI and/or PET/CT 
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every 3 to 12 months for stage IIB-IV (evidence 
level 2B) [7]. There is however no international 
consensus [8], reflecting the scarcity of studies 
assessing the value of routine PET/CT to detect 
relapse in this group of patients.
In this study, we will examine the diagnostic 
value of PET/CT for surveillance of patients 
treated for melanoma, and assess whether the 
accuracy of PET/CT differs if applied as part of 
a routine follow-up scheme or as an examina-
tion applied after a clinical suspicion of relapse. 
We will also compare the diagnostic accuracy 
of PET when applied with a full diagnostic CT 
respectively low-dose CT.
Materials and methods
Patients
This single-site retrospective study includes all 
patients treated for MM with at least one fol-
low-up PET or PET/CT during a 3-year period 
(Jan. 1st 2009 to Dec. 31st 2011) at Rigshospi- 
talet in Copenhagen. All referrals from the 
Department of Plastic Surgery to the PET-
department were extracted from our clinical 
database, returning a total of 754 referrals for 
a FDG-PET/CT scan. 49 patients with histology 
other than MM and 194 patients referred for 
initial staging or re-staging were excluded. This 
includes PET/CT scans performed earlier than 
three months after primary surgery which were 
considered as staging or re-staging. Eight 
patients (15 scans) were lost to follow-up leav-
ing 230 patients and 511 scans for the final 
analysis (Figure 1). The study was approved by 
The Danish Health Authority (RH-2013-30-
0978), and The Danish Data Protection Agency 
(2007-58-0015).
FDG PET/CT imaging
All patients were scanned on an integrated 
PET/CT scanner (Biograph TruePoint (16, 40 
and 64 slice), Siemens Medical Solution, 
Malvern PA; Biography 64 mCT, Siemens 
Medical Solutions, Malvern PA or Discovery LS, 
4 Slice, General Electric, Milwaukee, WI). 
Patients fasted for at least 6 hours before intra-
venous administration of FDG. A dosage of 
200-555 MBq FDG (4 MBq/kg) was adminis-
tered and after 60 minutes of rest the scan was 
performed. PET scans were combined with a 
low dose CT for attenuation correction or a CT 
of diagnostic quality acquired at 120-140 Kilo 
electron volts (KeV) with or without iodine 
based intravenous contrast agent.
As routine, the scans are performed as a whole 
body examination (WB, skull base to proximal 
thigh), but at the discretion of the referring clini-
cian an extended WB (from apex to toes) was 
performed. The attenuation corrected PET 
data were reconstructed iteratively using a 
3D ordered-subset expectation-maximization 
algorithm (OSEM), for scans performed on the 
Biography mCT this included point spread func-
tion and time of flight information. For initial 
reporting, all PET/CT scans were reviewed by a 
nuclear medicine physician and a radiologist.
Classification of FDG PET/CT scans and follow-
up
Original PET/CT reports were retrieved and re- 
viewed by a nuclear medicine specialist blinded 
to other examinations and clinical follow-up. For 
each scan location of findings were registered 
and each finding classified as benign, equivocal 
or malignant and other clinically relevant find-
ings were registered.
The reference standard was based on patho- 
logy reports, ultrasonography (US) and magnet-
ic resonance imaging (MRI) as well as clinical 
follow-up for at least 6 months after PET/CT. 
Figure 1. Flowchart for the selection of patients in-
cluded in the study.
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Figure 2. These images illustrate a series of surveillance PET/CT scans of a male born in 1951. He was operated 
for malignant melanoma on the back with micro-metastases to the left axilla and groin. The blue lines indicate the 
level of the inserted axial images. A: PET scan was performed as a routine control 3 years after surgery revealing 
a small, PET positive metastasis in the left lung (yellow arrow). This was surgically removed. Here after the patient 
was followed with PET-scan every 3-4 months. B: Three months after surgery PET revealed structural changes on 
CT and a slightly increased FDG-uptake reported as post-operative inflammation. C: After another 3 months PET 
revealed a highly increased focal FDG-uptake in the left lung (yellow arrow), reported as a new lung metastases. This 
was removed and confirmed by surgery. D: The next scan was without any suspicious findings. E: After another 3 
months (a total of 12 months after surgery) a malignant lymph node in the aortic-pulmonary window was diagnosed 
by PET (yellow arrow). The patient is currently, more than ten years after his initial diagnosis, alive with disseminated 
disease receiving treatment with aldesleukin. This case illustrates how a follow-up course can repeatedly diagnose 
recurrence before clinical manifestations, potentially improving patient survival.
Figure 3. This case illustrates the follow up course of a female born in 1993. After being surgically treated for a ma-
lignant melanoma on the right calf, she is followed with a PET scan every 6 months. (A-C) (first column) is from the 
PET scan performed 3 years after surgery, reported as normal. Six months later a new scan was performed (second 
column, D-F) and the small, PET positive lymph node in the left groin was reported as suspicious for malignancy 
(yellow arrow). This was disproved by biopsy. After another 6 months, a new PET scan was performed (third column, 
G-I), now with increasing FDG-uptake corresponding to the same lymph node in the left groin (yellow arrow). The 
lymph node was surgically removed, again with benign histology. This case is a typical example of how interpretation 
of PET positive lymph nodes can be difficult and often result in false positive reporting. The surveillance program 
was concluded 10 years after surgery with no evidence of relapse.
PET/CT for follow-up of patients with melanoma
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Imaging, clinical and pathology databases were 
searched for relevant entries for all patients. 
A true positive (TP) result was a PET/CT scan 
suggesting relapse, confirmed by pathology, 
MRI, or US within 6 months.
A false positive (FP) result was a PET/CT scan 
suggesting relapse, but disproved by pathology, 
MRI, or US within 6 months.
A true negative (TN) result was a PET/CT scan 
with no signs of relapse, and no relapse detect-
ed by pathology, MRI, US or at clinical follow-up 
for at least 6 months. 
A false negative (FN) result was a PET/CT scan 
with no relapse, but where a relapse was la- 
ter diagnosed by biopsy, MRI, US or at clinical 
follow-up within 6 months.
Statistical analysis
Statistical analyses were performed using 
Statistical Package for the Social Sciences 
of relapse and the diagnostic accuracy of PET/
CT compared to PET with low-dose CT and of 
PET/CT in the following sub-groups: 1) patients 
referred with a clinical suspicion of relapse and 
2) regular follow-up due to the initial high risk 
staging were performed using a z-test for com-
parison of two independent proportions and 
ratios of TP, FP, TN and FN by the Pearson’s 
Chi-squared test. Mean age was compared 
by a t-test for two independent samples. 
Applied p-values are two-sided and considered 
to be significant when p<0.05, no correction 
for multiple comparisons was performed.
Results
Baseline patient characteristic and follow-up
238 patients (526 scans) had been treated for 
MM in the period from Jan. 1st 2009 to Dec. 
31st 2011 and been subjected to one or more 
PET/CT scans for follow-up (Figure 1). Two illus-
trative examples are presented in Figures 2 
and 3. Patient characteristics are described in 
Table 1. Patient characteristics, including information on initial AJCC* 
stage and reason for referral to PET scan
Age (years) median 53
Age (years) range 11-89
Sex (male/female) 117/121
Stage after initial resection Number of patients Percentage
Ia 22 9.2
Ib 31 13
IIa 26 10.9
IIb 12 5.5
IIc 8 3.4
IIIa 54 22.7
IIIb 40 16.8
IIIc 8 3.4
IV 22 9.2
NA 15 6.3
Total 238 100
Cause of referral Number of scans Percentage
Relapse likely based on another modality 29 5.5
Evaluation after finding of solitary metastasis 46 8.7
Treatment evaluation 6 1.1
Clinical suspicion of relapse 92 17.5
Planned control due to initial high-risk staging 352 66.9
Patients’ wish 1 0.2
Total 526 100
*American Joint Committee on Cancer.
(SPSS) 24.0 (IBM SPSS 
Statistics for Mac; IBM 
Corporation, Armonk, 
NY, USA). Sensitivity was 
defined as: [number of 
true positive cases, TP]/
[total number of true 
positive and false nega-
tive cases]). Specificity 
was defined as: [number 
of true negative cases, 
TN]/[total number of fal- 
se positive, FP and true 
negative cases]. Positive 
predictive value (PPV) 
was defined as: [number 
of true positive cases]/
[total number of true 
positive and false posi-
tive cases]. Negative 
predictive value (NPV) 
was defined as: [number 
of true negative cases]/
[total number of true 
negative and false nega-
tive cases, FN]. Confi- 
dence intervals were 
estimated using Wilson 
score method. Compa- 
rison of the prevalence 
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Table 1. The scans were divided into groups 
according to the reason for referral (Table 1): 
Relapse very likely based on another modality 
(n=29), evaluation after finding of solitary 
metastasis (n=46), treatment evaluation (n=6), 
clinical suspicion of relapse (n=92), planned 
control due to initial high-risk staging (n=352) 
and the patients’ wish (n=1). The majority of 
scans were done as part of planned follow-up 
scheme (n=352, 67%) or due to a known or 
suspected relapse (n=29+92, 23%). Of the 
526 scans 130 (25%) scans were PET-positive, 
365 (69%) PET-negative and 28 (5%) equivo- 
cal. In 3 scans (0.6%) there were other clinical 
relevant findings. 
Classification and diagnostic accuracy
Follow-up was complete in 230 patients (511 
scans). Ninety four of 126 (75%) PET/CT scans 
suggesting relapse were confirmed or dispro- 
ved by pathology and 8 (6%) by MRI or US. In 
the remaining 24 scans (19%) no other diag-
nostic confirmation was sought, mainly due to 
findings of multiple metastases clinically de- 
emed as certain proof of relapse.
As expected the clinical follow-up after a ne- 
gative PET/CT scan was less thorough: 316 of 
357 negative PET/CT scans (89%) were either 
confirmed or disproved based on clinical fol- 
low-up for 6 months. 
For all scans with a complete follow-up (n= 
511) sensitivity and specificity was 89% and 
92% respectively and the positive and negative 
predictive value was 78% and 97% respectively 
in the primary analysis (Table 2). Including equi- 
vocal scans as positive for relapse sensitivity 
and specificity was 89% and 87%, respectively, 
and the positive and negative predictive value 
was 67% and 97%, respectively. Including equi- 
vocal scans as negative, sensitivity and speci-
ficity was 87% and 93%, and the positive and 
negative predictive value was 78% respective- 
ly 96%. There was no significant difference be- 
tween the two approaches. 
The diagnostic values of PET/CT, when strati-
fied for reason for referral, are reported in Table 
3. Overall, no statistical significance between 
the two groups could be found: The NPV in the 
both groups was very high: 94% in the high risk 
group and 98% in low risk group. The PPV and 
the specificity are lower in the low risk group 
(NS), possibly reflecting the difference in pre- 
valence of relapse in the two groups (33% re- 
spectively 15%, p<0.0001). 
Comparing the diagnostic accuracy of PET per-
formed with diagnostic CT respectively low-do- 
se CT (Table 3) the overall accuracy of PET with 
low-dose CT appears higher than that of PET/
CT (96% respectively 90%, p<0.0001). No dif-
ference between WB (skull-base to mid-thigh) 
Table 2. Classification of PET/CT results and diagnostic accuracy as calculated in primary as well as 
sensitivity analysis
Number of scans*
Relapse confirmed
Lost to follow-up Total
Yes No
PET/CT + Relapse 98 28 4 130
- Relapse 12 345 8 365
Equivocal 3 22 3 28
Other 0 3 0 3
Total 113 398 15 526
Diagnostic Accuracy [95% CI] Primary analysis
Sensitivity analysis†
Equivocals included as 
positive for relapse
Equivocals included as 
negative for relapse
Sensitivity 0.89 [0.82-0.94] 0.89 [0.82-0.94] 0.87 [0.79-0.92]
Specificity 0.92 [0.89-0.95] 0.87 [0.84-0.90] 0.93 [0.90-0.95]
Positive Predictive Value 0.78 [0.70-0.84] 0.67 [0.59-0.74] 0.78 [0.70-0.84]
Negative Predictive Value 0.97 [0.94-0.98] 0.97 [0.94-0.98] 0.96 [0.94-0.98]
Overall accuracy 0.92 [0.89-0.94] 0.88 [0.85-0.90] 0.92 [0.89-0.94]
*Numbers in red included in primary analysis. †Equivocal included as positive respectively negative for sensitivity analysis. The 
remaining 18 scans (lost to follow-up n=15 or with findings not related to MM n=3) not included for further analysis.
PET/CT for follow-up of patients with melanoma
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compared to extended WB (including legs) was 
found. 
In 7 (3%) patients a relapse was diagnosed less 
than 6 months after a negative PET/CT (false 
negative, listed in Table 4): In 5 patients a cuta-
neous relapse was found, in one metastases to 
iliac lymph nodes was found during HILP (hyper-
thermic isolated limb perfusion) 3 weeks after 
PET and one patient was diagnosed with bilat-
eral lung metastases 3 months after PET/CT. A 
false positive PET/CT scan was seen at some 
point in 21 patients (9%). Of all the false posi-
tive findings (28 scans) 17 were in lymph nodes 
(refer to Figure 3 for an example), 3 were in the 
lungs, 3 were located at the trunk or extremi-
ties, 1 in the gastro intestinal canal, 1 in the 
urinary tract and 3 in other locations. 
Discussion
The purpose of this study was to assess the 
value of PET/CT for surveillance of patients 
treated for MM with curative intend. It was ana-
lyzed through a retrospective, cross-sectional 
design, which demonstrated that PET/CT has a 
moderate sensitivity and specificity (89% and 
92%) but a high NPV (97%) for detection of re- 
lapse. The amount of data on surveillance of 
MM patients with PET/CT is scarce and very 
few original studies have been published on 
this topic [9-11]. Nonetheless, PET/CT for sur-
veillance has gained widespread acceptance 
and has been a part of e.g. Danish guidelines 
since 2015. To the best of our knowledge, the 
current study is the largest focusing strictly on 
surveillance published to date. 
The main rationale behind close follow-up of 
patients with MM is the hypothesis that early 
detection of relapse renders salvage therapy 
possible and prolongs survival. This seems in- 
tuitively correct, but nonetheless, remains to 
be proven in a prospective, randomized trial. 
A recent analysis based on the National Com- 
prehensive Cancer Network guidelines for mel-
anoma surveillance, confirms that routine ima- 
ging surveillance effectively predicted absence 
of disease, but only resulted in minimal gains 
in life expectancy [12]. A recent retrospective 
study including 110 patients found that PET/CT 
Table 3. Comparison of diagnostic accuracy between high vs. low risk patients and diagnostic accu-
racy between PET with diagnostic CT vs. PET with low dose CT
Diagnostic Accuracy [95% CI] High Risk* Low Risk† PET with low dose CT PET/CT (diagnostic CT)
Sensitivity 0.89 [0.75-0.96] 0.92 [0.80-0.97] 0.93 [0.78-0.98] 0.89 [0.80-0.94]
Specificity 0.88 [0.78-0.93] 0.94 [0.90-0.96] 0.97 [0.93-0.99] 0.90 [0.85-0.93]
Positive Predictive Value 0.79 [0.64-0.88] 0.71 [0.59-0.81] 0.87 [0.71-0.95] 0.75 [0.65-0.82]
Negative Predictive Value 0.94 [0.86-0.98] 0.98 [0.96-0.99] 0.99 [0.95-0.99] 0.96 [0.93-0.98]
Overall accuracy 0.88 [0.81-0.93] 0.93 [0.90-0.96] 0.96 [0.92-0.98] 0.90 [0.86-0.92]
Prevalence of relapse 0.34 [0.25-0.43] 0.15 [0.11-0.19] 0.18 [0.13-0.24] 0.25 [0.21-0.30]
Mean age 44.8 [SD 20.8] 54.8 [SD 17.7]
*High risk = patients with a clinical suspicion of relapse or relapse likely based on other modality. †Low risk = Planned control 
due to initial high-risk staging.
Table 4. Description of patients with a diagnosed relapse who had a negative PET or PET/CT scan 
less than 6 months before the relapse
Patient Indication Scan Findings
1 Planned control PET/CT, wb Cutaneous relapse in close proximity to surgical scar, found by inspection and verified by 
histology (app. 1 week after PET/CT)
2 Planned control PET/CT, wb Subcutaneous relapse in the occipital region, found by inspection and verified by histology 
(app. 3 months after PET/CT)
3 Clinical suspicion PET/CT, wb Bilateral lung metastases found and confirmed by cytology app. 3 months after PET/CT
4 Clinical suspicion PET/CT, extended wb Multiple cutaneous metastases on crus, found by inspection and verified by histology (app. 
1 week after PET/CT)
5 Clinical suspicion PET/CT, extended wb Metastases from MM found in 8/9 iliac lymph nodes removed during HRP 3 weeks after 
PET/CT
6 Planned control PET/CT, wb Cutaneous relapse, found by inspection and verified by histology (app. 1 week after PET/CT)
7 Clinical suspicion PET/CT, wb Cutaneous relapse, found by inspection and verified by histology (app. 1 week after PET/CT)
PET/CT for follow-up of patients with melanoma
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detected a recurrence in 1 of 4 asymptomatic 
melanoma patients, but without any impact on 
survival [11].
Other studies examining the ability of PET/CT 
to detect distant metastases after a MM-diag- 
nosis, shows a relatively higher sensitivity and 
specificity compared to our findings [13]. Akcali 
[13] investigated patients with stage III and IV 
finding the sensitivity of PET/CT to be 91% and 
NPV 96%. Wider [14] found the sensitivity and 
NPV of PET/CT in the follow-up of malignant 
melanoma to be 87% respectively 93%. Based 
on 7 original studies Danielsen et al. [9] investi-
gated PET in follow-up of cutaneous malignant 
melanoma in a systematic review and found a 
pooled sensitivity and NPV of 96% and 95%. 
The relatively high sensitivity in this meta-anal-
ysis may be explained as the included studies 
are based mostly on high stage (III&IV) patients, 
and some studies have a positive PET/CT as 
an inclusion criteria resulting in a sensitivity at 
100%. 
Overall, the NPV in our study was high, confirm-
ing that PET/CT can effectively rule out relap- 
se. In total we observed 113 relapses in 74 
patients. 98 of these were diagnosed by PET/
CT. Thus 15 of 365 (4%) negative scans were 
false negative for relapse at any time, but only 
7 (2%) patients experienced a relapse within 6 
months of a negative PET/CT. The majority of 
the false negative findings in this study were 
located to the skin, underlining the importance 
of clinical inspection, also in the era of PET.
On the downside, this study found a relatively 
low positive predictive value (PPV), particularly 
in the group of patients with no clinical suspi-
cion of recurrence (71%). Thus, in this group 
almost 30% of the PET/CT scans with a suspi-
cion of relapse were later proved to be false 
alarm. This may cause anxiety and can poten-
tially lead to further invasive diagnostic proce-
dures and draws on hospital resources.
The reason for the substantial number of false 
positive results in this, as well as in previous 
studies, is the well-known increased FDG-up- 
take by inflammatory cells. This corresponds 
well to the fact that the majority of false posi-
tive findings in our study were located to lymph 
nodes. Our sensitivity analysis also indicates 
that a conservative approach (equivocal scans 
interpreted as negative) may result in a higher 
accuracy, but this will be dependent on local 
settings and needs confirmation in larger 
studies.
When using PET/CT for routine follow-up of MM 
patients, many of them being young and poten-
tially cured for their MM, it is preferable to 
reduce the amount of radiation to a minimum. 
We investigated the performance of PET/CT 
with a low-dose CT versus PET/CT with a whole 
body diagnostic CT and found no statistical 
significant difference in sensitivity, specificity, 
NPV or PPV. Surprisingly PET with low-dose CT 
appeared to have a higher overall accuracy 
than PET/CT, primarily reflecting the differen- 
ce in the number of false positive scans (3% 
respectively 8%, p=0.04). This may be attribut-
ed to the fact that it is two different groups of 
patients assigned to each investigation: typi-
cally younger patients will be referred for PET 
with low-dose CT (mean age in this study: 44.8 
yrs.), whereas older patients or patients with a 
higher risk of malignancy will be referred to 
PET with diagnostic CT (mean age 54.0 yrs., 
p<0.0001). In the older patient population, 
more inflammatory findings can be expected. 
Similarly, Pfluger [15] found that PET with con-
trast-enhanced CT versus plain low-dose CT 
had similar specificity. These findings make it 
reasonable to believe that diagnostic PET/CT 
and PET with low-dose CT performs equally well 
in ruling out relapses, especially in younger 
patients.
Conclusion
This study demonstrated that PET/CT has a 
moderate specificity and sensitivity but a high 
negative predictive value (97%) for follow-up of 
patients treated for MM. Approximately 1/10 
patients experienced a false positive result, 
most frequent among patients undergoing a 
routine PET/CT without a clinical suspicion of 
relapse. Whether the high accuracy in ruling 
out relapse translates into a clinical benefit 
remains to be proven. 
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